# A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

> **NCT00431340** · PHASE2 · TERMINATED · sponsor: **Valerio Therapeutics** · enrollment: 4 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** PXD101

## Key facts

- **NCT ID:** NCT00431340
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Terminated due to dose limiting toxicity
- **Last updated:** 2015-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431340, "A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00431340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*